In The Media

Fund Focus: International Biotech Trust

What it does Invests in companies developing new drugs. The team believe that an ageing global population means there is a growing need for these. What it invests in It looks for companies with an experienced management team targeting an unmet need. About 41% of its...

read more

Get a 4% dividend from the future of medicine

Biotechnology is an exciting industry, where technology creates medicine tailored to individuals.   This is seen as the future of healthcare, as instead of being given one size fits all drugs patients can get treatments that will work better for them and fight...

read more

Winner – Citywire Best Specialist Equities 2017

International Biotechnology Trust (IBT) triumphed in an eclectic category at the Citywire Investment Trust Awards, seeing off competition from property, technology and environmental funds to be crowned best Specialist Equities trust.   Our awards analysed trusts'...

read more

Dividends and biotech: a blockbuster combination?

Anyone in doubt about the revitalising effect dividends can have on an investment trust’s share price need only look at International Biotechnology Trust (IBT).   Managers of the £223 million closed-end fund hope it may soon be able to issue shares for the first...

read more

Trust in a third way for returns on biotech

Biotechnology companies tend to come in two types: those like Glaxosmithkline and Astrazeneca that offer investors a good and reliable income, and those that pay no dividends but are attractive prospects for that blockbuster drug that might, or might not, get through...

read more

Disclaimer

  • You are seeing this because you are accessing IBT’s website for the first time.

 

  • The information on this website may only be suitable for certain types of investors and is not intended to be used or relied upon by any other person.

 

  • An investment with IBT may contain significant risks and is intended only for sophisticated investors who meet certain eligibility criteria.

 

  • The material on this website is intended to be viewed only by persons resident in the EEA.

 

  • The information on this website is not an offer to sell or a solicitation of an offer and does not constitute investment advice.

 

  • No representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information or opinions contained therein.

 

  • The information on this website may constitute financial promotion for the purposes of the Financial Services and Markets Act 2000 (“FSMA”).

 

Dwayne Haskins Authentic Jersey